Nivalis Therapeutics, Inc. (ALPN) Lowered to Strong Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Nivalis Therapeutics, Inc. (NASDAQ:ALPN) from a hold rating to a strong sell rating in a research note published on Thursday morning.

According to Zacks, “Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington. “

A number of other brokerages also recently commented on ALPN. Ladenburg Thalmann Financial Services started coverage on Nivalis Therapeutics in a research note on Thursday, July 27th. They issued a buy rating and a $17.00 target price on the stock. ValuEngine upgraded Nivalis Therapeutics from a sell rating to a hold rating in a research note on Thursday, July 27th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company. Nivalis Therapeutics has an average rating of Hold and an average target price of $5.75.

Shares of Nivalis Therapeutics (NASDAQ ALPN) traded down 2.14% during midday trading on Thursday, hitting $10.05. The company had a trading volume of 18,190 shares. The firm’s market cap is $6.69 million. Nivalis Therapeutics has a one year low of $7.20 and a one year high of $26.08. The company’s 50 day moving average is $10.94 and its 200 day moving average is $9.68.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at

Nivalis Therapeutics Company Profile

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Analyst Recommendations for Nivalis Therapeutics (NASDAQ:ALPN)

Receive News & Ratings for Nivalis Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nivalis Therapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply